<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cancer and Leukemia Group B (CALGB) study 9111 chemotherapy regimen for acute lymphoblastic leukemia in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cancer and Leukemia Group B (CALGB) study 9111 chemotherapy regimen for acute lymphoblastic leukemia in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Cancer and Leukemia Group B (CALGB) study 9111 chemotherapy regimen for acute lymphoblastic leukemia in adults</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single" colspan="4">Course I: Induction (4 weeks)</td> </tr> <tr> <td class="subtitle2_left" colspan="4">For patients &lt;60 years old:</td> </tr> <tr> <td class="indent1">Cyclophosphamide</td> <td>IV</td> <td>1200 mg/m<sup>2</sup></td> <td>Day 1</td> </tr> <tr> <td class="indent1">Daunorubicin</td> <td>IV</td> <td>45 mg/m<sup>2</sup>/day</td> <td>Days 1-3</td> </tr> <tr> <td class="indent1">Vincristine</td> <td>IV</td> <td>2 mg</td> <td>Days 1, 8, 15, 22</td> </tr> <tr> <td class="indent1">Prednisone</td> <td>PO</td> <td>60 mg/m<sup>2</sup>/day</td> <td>Days 1-21</td> </tr> <tr> <td class="indent1">Asparaginase (E. coli)</td> <td>SC/IM</td> <td>6000 units/m<sup>2</sup></td> <td>Days 5, 8, 11, 15, 18, 22</td> </tr> <tr> <td class="subtitle2_left" colspan="4">For patients ≥60 years old:</td> </tr> <tr> <td class="indent1">Cyclophosphamide</td> <td>IV</td> <td>800 mg/m<sup>2</sup></td> <td>Day 1</td> </tr> <tr> <td class="indent1">Daunorubicin</td> <td>IV</td> <td>30 mg/m<sup>2</sup>/day</td> <td>Days 1-3</td> </tr> <tr> <td class="indent1">Vincristine</td> <td>IV</td> <td>2 mg</td> <td>Days 1, 8, 15, 22</td> </tr> <tr> <td class="indent1">Prednisone</td> <td>PO</td> <td>60 mg/m<sup>2</sup>/day</td> <td>Days 1-7</td> </tr> <tr> <td class="indent1">Asparaginase (E. coli)</td> <td>SC/IM</td> <td>6000 units/m<sup>2</sup></td> <td>Days 5, 8, 11, 15, 18, 22</td> </tr> <tr> <td class="subtitle2_left" colspan="4">All patients receive filgrastim (G-CSF) 5 mcg/kg subcutaneously once per day starting on day 4 and continuing until the ANC is &gt;1000/microL on two consecutive determinations &gt;24 hours apart.</td> </tr> <tr> <td class="subtitle1_single" colspan="4">Course IIA: Early intensification (4 weeks; repeat once for Course IIB)</td> </tr> <tr> <td>Intrathecal methotrexate</td> <td>IT</td> <td>15 mg</td> <td>Day 1</td> </tr> <tr> <td>Cyclophosphamide</td> <td>IV</td> <td>1000 mg/m<sup>2</sup></td> <td>Day 1</td> </tr> <tr> <td>Mercaptopurine</td> <td>PO</td> <td>60 mg/m<sup>2</sup>/day</td> <td>Days 1-14</td> </tr> <tr> <td>Cytarabine</td> <td>SC</td> <td>75 mg/m<sup>2</sup>/day</td> <td>Days 1-4, 8-11</td> </tr> <tr> <td>Vincristine</td> <td>IV</td> <td>2 mg</td> <td>Days 15, 22</td> </tr> <tr> <td>Asparaginase (E. coli)</td> <td>SC/IM</td> <td>6000 units/m<sup>2</sup></td> <td>Days 15, 18, 22, 25</td> </tr> <tr> <td class="subtitle1_single" colspan="4">Course III: CNS prophylaxis and interim maintenance (12 weeks)</td> </tr> <tr> <td>Cranial irradiation</td> <td> </td> <td>2400 cGy</td> <td>Days 1-12</td> </tr> <tr> <td>Intrathecal methotrexate</td> <td>IT</td> <td>15 mg</td> <td>Days 1, 8, 15, 22, 29</td> </tr> <tr> <td>Mercaptopurine</td> <td>PO</td> <td>60 mg/m<sup>2</sup>/day</td> <td>Days 1-70</td> </tr> <tr> <td>Methotrexate</td> <td>PO</td> <td>20 mg/m<sup>2</sup></td> <td>Days 36, 43, 50, 57, 64</td> </tr> <tr> <td class="subtitle1_single" colspan="4">Course IV: Late intensification (8 weeks)</td> </tr> <tr> <td>Doxorubicin</td> <td>IV</td> <td>30 mg/m<sup>2</sup></td> <td>Days 1, 8, 15</td> </tr> <tr> <td>Vincristine</td> <td>IV</td> <td>2 mg</td> <td>Days 1, 8, 15</td> </tr> <tr> <td>Dexamethasone</td> <td>PO</td> <td>10 mg/m<sup>2</sup>/day</td> <td>Days 1-14</td> </tr> <tr> <td>Cyclophosphamide</td> <td>IV</td> <td>1000 mg/m<sup>2</sup></td> <td>Day 29</td> </tr> <tr> <td>Thioguanine</td> <td>PO</td> <td>60 mg/m<sup>2</sup>/day</td> <td>Days 29-42</td> </tr> <tr> <td>Cytarabine</td> <td>SC</td> <td>75 mg/m<sup>2</sup>/day</td> <td>Days 29-32, 36-39</td> </tr> <tr> <td class="subtitle1_single" colspan="4">Course V: Prolonged maintenance (until 24 months from diagnosis)</td> </tr> <tr> <td>Vincristine</td> <td>IV</td> <td>2 mg</td> <td>Day 1 of every 4 weeks</td> </tr> <tr> <td>Prednisone</td> <td>PO</td> <td>60 mg/m<sup>2</sup>/day</td> <td>Days 1-5 of every 4 weeks</td> </tr> <tr> <td>Mercaptopurine</td> <td>PO</td> <td>60 mg/m<sup>2</sup>/day</td> <td>Days 1-28</td> </tr> <tr> <td>Methotrexate</td> <td>PO</td> <td>20 mg/m<sup>2</sup></td> <td>Days 1, 8, 15, 22</td> </tr> </tbody></table>
<!--[if gte mso 9]><xml>
<mso:CustomDocumentProperties>
<mso:Specialty msdt:dt="string">7</mso:Specialty>
<mso:Edit_Table msdt:dt="string">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=24929&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>
</mso:CustomDocumentProperties>
</xml><![endif]-->
</div><div class="graphic_footnotes">ANC: absolute neutrophil count; IT: intrathecal; IV: intravenous; IM: intramuscular; PO: oral; SC: subcutaneous.</div><div class="graphic_reference">Data from: Acute Leukemias VI: Prognostic factors and treatment strategies, Buchner T, Hiddeman W, Wormann B (Eds), Springer-Verlag, Berlin 1997. p.677; Larson RA, Dodge RK, Burns CP, Blood 1995; 85:2025; and Larson RA, Dodge RK, Linker CA, et al. Blood 1998; 92:1556-1564.</div><div id="graphicVersion">Graphic 67471 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
